John Michael Ketcham

USPTO Granted Patents = 22 (Patent Applications = 17)

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 5 (Patent Applications = 17)

Average Co-Inventor Count = 7.6

ph-index = 4

Forward Citations = 37(Granted Patents)

Location History:

San Mateo, CA (US) (2019 - 2022)
Carlsbad, CA (US) (2023)
San Diego, CA (US) (2020 - 2024)

Company Filing History:

14 out of 38

Mirati Therapeutics, Inc.

patents

6 out of 13

Rapt Therapeutics, Inc.

where one patent can have more than one assignee

Years Active: 2019-2025

where 'Filed Patents' based on already Granted Patents

22 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12421228 - Naphthyridine derivatives as PRC2 inhibitors (2025-09-23),

2. 12371435 - Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors (2025-07-29),

3. 12304915 - SOS1 inhibitors (2025-05-20),

4. 12280055 - Combination therapies (2025-04-21),

5. 12252493 - Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer (2025-03-18),

6. 12098139 - Chemokine receptor modulators and uses thereof (2024-09-24),

7. 11964989 - KRas G12D inhibitors (2024-04-23),

8. 11702418 - SOS1 inhibitors (2023-07-18),

9. 11492351 - MTA-cooperative PRMT5 inhibitors (2022-11-08),

10. 11485738 - Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors (2022-11-01),

11. 11479551 - MTA-cooperative PRMT5 inhibitors (2022-10-25),

12. 11453683 - KRas G12D inhibitors (2022-09-27),

13. 11384064 - Chemokine receptor modulators and uses thereof (2022-07-12),

14. 11220509 - Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors (2022-01-11),

15. 11192879 - Chemokine receptor modulators and uses thereof (2021-12-07),

Title: The Innovative Journey of John Michael Ketcham

Introduction

John Michael Ketcham is a distinguished inventor based in San Diego, California. With a remarkable portfolio of 13 patents, he has made significant contributions to the field of biochemistry, particularly in the development of compounds for cancer treatment. His innovative approach and dedication to research have positioned him as a prominent figure in the pharmaceutical industry.

Latest Patents

Among his latest patents are two noteworthy inventions: the development of substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors and methods utilizing SOS1 inhibitors. The former involves a unique process for preparing a compound through the reaction of specific chemical formulas in the presence of a palladium catalyst. The latter patent focuses on treating cancer with compounds that inhibit the activity of Son of sevenless homolog 1 (SOS1), alongside pharmaceutical compositions containing these innovative compounds.

Career Highlights

John has built a successful career, holding influential positions in reputable companies such as Mirati Therapeutics, Inc. and Array Biopharma Inc. His work in these organizations has been instrumental in advancing therapeutic options for cancers, showcasing his expertise in biochemical innovation and patent development.

Collaborations

Throughout his career, John has collaborated with notable professionals, including Matthew Arnold Marx and Aaron Craig Burns. These partnerships have contributed to the advancement of research and innovation in the pharmaceutical field, reinforcing the importance of teamwork in achieving breakthroughs.

Conclusion

John Michael Ketcham exemplifies the spirit of innovation in the realm of biochemical research and patent development. With multiple patents to his name and significant industry collaborations, he continues to pave the way for advancements in cancer treatment and pharmaceuticals, demonstrating the power of creative thinking and scientific inquiry.

This text is generated by artificial intelligence and may not be accurate.